Comparative Pharmacology
Head-to-head clinical analysis: FLUDROCORTISONE ACETATE versus MEDROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUDROCORTISONE ACETATE versus MEDROL.
FLUDROCORTISONE ACETATE vs MEDROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mineralocorticoid receptor agonist; promotes sodium reabsorption and potassium excretion in renal distal tubules, increasing extracellular fluid volume. Also has glucocorticoid activity.
Methylprednisolone is a synthetic glucocorticoid that binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammatory cytokines (e.g., IL-1, IL-2, TNF-alpha). It inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis.
0.1 mg orally once daily, range 0.05-0.2 mg/day
4 to 48 mg orally once daily or every other day, depending on condition. Initial dose may be up to 48 mg/day.
None Documented
None Documented
Terminal elimination half-life is 3.5 hours (range 2–5 h); clinical effect duration exceeds half-life due to mineralocorticoid receptor binding.
Terminal half-life of methylprednisolone is 2.5-3.5 hours; for the active metabolite (prednisolone), half-life is 2.1-3.5 hours. Clinical context: Despite short half-life, pharmacodynamic effects persist beyond plasma presence due to receptor-mediated actions.
Renal (80%) as inactive metabolites; less than 5% unchanged; minor biliary/fecal elimination.
Renal (approximately 80-90% as metabolites, <5% unchanged); biliary/fecal (minor, <5%)
Category D/X
Category C
Corticosteroid
Corticosteroid